ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Lymphoma, Non-Hodgkin is on this study

  • ClinicalTrials.gov files the study under Lymphoma, Non-Hodgkin.
  • GPT-6 Astra (Medium) judged the term right family, but the study is about something narrower. Oct 20 (day only)
  • It is the study's main condition, by the main-condition rule: the study is compared with others under Lymphoma, Non-Hodgkin.
  • Rule based: a general category, not a disease.
3 links0 made here, not in the record5 judgments2 judges (the rules as one: Rule based)1 record change seen
GPT-6 Astra (Medium)Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT07607925A Study to Evaluate Safetyand Clinical Activity ofGSK5926371 in AdultParticipants With Relapsedor Refractory B-NHLGlaxoSmithKlinePhase 1/Phase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 30 · ClinicalTrials.gov record · Version of 2026-10-30Version of 2026-10-30CONDITIONSLymphoma, Non-HodgkinThe registry's MeSH filing›Oct 20 · GPT-6 Astra (Medium) · Finer: Lymphoma, B-CellNov 14 · Rule based · General: a category, not a diseaseAs of now · Rule based · Main conditionMain conditionRecurrenceThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseDRUGSINT024244Entry “GSK5926371”, read by our name …›Nov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Oct 30 · changes seen, not judgments
Oct 20Lymphoma, Non-HodgkinGPT-6 Astra (Medium)Finer: Lymphoma, B-CellCurrent
Nov 14Lymphoma, Non-HodgkinRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14RecurrenceRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 18INT024244Rule based · role ruleTestedCurrent
As of nowLymphoma, Non-HodgkinRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.